Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Recombinant human ADA2 and ADA2 fusion proteins and methods for treating ADA2 deficiencies

Recombinant human ADA2 and ADA2 fusion proteins and methods for treating ADA2 deficiencies

US Patent 10557161 · Granted Feb 11, 2020

Estimated economic value: $177,943,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Muscle targeting complexes and uses thereof for treating myotonic dystrophy2025
United states2025
Complexes comprising an anti-transferrin receptor antibody linked to an oligonuc2025
Wireless charger2025
Muscle targeting complexes and formulations for treating myotonic dystrophy2025
Muscle targeting complexes and uses thereof for treating dystrophinopathies2025
Complexes comprising an anti-transferrin receptor antibody linked to an oligonic2025
Muscle targeting complexes and uses thereof for treating dystrophinopathies2025
Muscle targeting complexes and uses thereof for treating dystrophinopathies2025
Complexes comprising an anti-transferrin receptor antibody linked to an oligonuc2025
Muscle-targeting complexes comprising an anti-transferin receptor antibody linke2025
Muscle targeting complexes and uses thereof for treating dystrophinopathies2025